N/A N=51 Obesity and Nonalcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
Primary: Hepatic Insulin Sensitivity Index (HISI) — 0.8; 1.4 [10000/(μmol/min)x(mU/L)] — p=<0.019
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
NAFLD · Nonalcoholic Fatty Liver · NASH - Nonalcoholic Steatohepatitis
Primary: Intrahepatic Lipid Content (IHL, Percent Liver Fat) — 3.9 absolute change in percentage liver fat — p=0.4
Phase 2 N=80 Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver · Nonalcoholic Steatohepatitis
Primary: Absolute Change in Intrahepatic Lipid Content, by 1H-MRS — -6.6; 3.6 Mean absolute percentage change
Phase 2 N=53 Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Change in Intrahepatic Lipid Content Between Baseline and 6 Months as Measured by 1H-magnetic Resonance Spectroscopy (1H-MRS). Endpoints Were Assessed at Baseline and 6…
N/A N=4 Metabolomic Analysis of Hepatic Insulin Resistance
Type 2 Diabetes · Obesity
Primary: Insulin Sensitivity — 8 m value — p=<0.05
N/A N=55 Intermittent Fasting and Metabolic Dysfunction Associated Fatty Liver Disease
Intermittent Fasting · Metabolic Dysfunction-Associated Fatty Liver Disease
Primary: Transient Elastography-Controlled Attenuation Parameter — 319.5; 343.5; 291.5; 285.0 db/m
Phase 2 N=26 Treating Nonalcoholic Steatohepatitis (NASH) With Metformin
Hepatitis
Primary: Change in the Histological NASH Activity Index at 48 Weeks Compared With Baseline (Number of Participants in Each Change Category) — 9; 11; 5; 1 participants — p=<0.001
N/A N=80 Alternate Day Fasting, Exercise, and NAFLD
Non-Alcoholic Fatty Liver Disease · Obesity
Primary: Change in Hepatic Steatosis — -2.25; -1.3; -5.48; -0.17 liver fat percentage
Phase 2 N=12 Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome
Metabolic Syndrome
Primary: Change in Hepatic Lipogenesis — 5.6 abs percent change fasting lipogenesis
N/A N=1,061 Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages
Fatty Liver, Nonalcoholic · Diabetes Mellitus, Type 2
Primary: Action on Suspected Advanced Liver Fibrosis — 55; 4 Participants
Phase 2 N=255 Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
Nonalcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis With Liver Fibrosis
Primary: Mean Proportion of Participants Achieving Resolution of NASH Without Worsening/Improvement of Fibrosis by >=1 Stage Without Worsening of NASH/Both Based on Assessment by…
Phase 2 N=18 Treating Nonalcoholic Steatohepatitis With Pioglitazone
Hepatitis
Primary: Number of Patients With Improvement in Liver Histology — 12 participants
N/A N=70 Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease · Non-alcoholic Steatohepatitis
Primary: Percent Change in Hepatic Steatosis as Measured by Controlled Attenuation Parameter (CAP) Score — -13.0; 8.7 percent change
Phase 4 N=103 Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids
Non-Alcoholic Fatty Liver Disease
Primary: Percentage of Liver Fat — -7.9; -4.6 percentage of liver fat — p=0.48
Phase 2 N=275 Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Non-Alcoholic Steatohepatitis (NASH)
Primary: Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) — 21…
N/A N=104 Investigation of Synbiotic Treatment in NAFLD
Non-Alcoholic Fatty Liver Disease
Primary: Change in Liver Fat — -3.8; -6.0 percentage of liver fat — p==0.05
Phase 4 N=105 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
Nonalcoholic Steatohepatitis
Primary: Liver Histology (Kleiner's et al Criteria, Hepatology 2005) — 7; 13; 24 Participants
Phase 2 N=9 Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)
Fatty Liver Disease, Nonalcoholic
Primary: Non-alcoholic Steatohepatitis Score as Determined by Liver Histopathology at 12 Months — 5 units on a scale — p=0.015
N/A N=14 Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery
NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease
Primary: Percent Change in Liver Fat Between Baseline and 12 Weeks Post-surgery — -16.4 percent change
N/A N=8 Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study
Non-Alcoholic Fatty Liver Disease
Primary: Participants With Normalized Liver Enzyme Levels — 0; 0 Participants
Phase 2 N=164 A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Non-alcoholic Steatohepatitis
Primary: Percent Change From Baseline in Whole Liver Fat at Week 16 — -3.21; -16.12; -4.36 Percent change — p=0.0696
Phase 2 N=99 A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Primary: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 — 8.14; -40.01; -30.14; -40.13 percent change — p=0.0000
Early Phase 1 N=9 Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease
Fatty Liver
Primary: Hepatic Fatty Acid Oxidation
N/A N=28 NASH Fitness Intervention in Thrombosis Trial (NASHFit)
Liver Diseases · Blood Disorder · Digestive System Disease
Primary: PAI-1 Level — 151.4; 176.2 ng/mL
N/A N=126 Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic Fatty Liver Disease
Primary: Hematic Levels of Hepatic Enzymes AST — 35.4; 37.5; 31.6; 31.2 IU/L — p=<0.05
Phase 2 N=50 Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
Primary: Percentage Change in Liver Fat Relative to Baseline Assessed by MRI-PDFF — 13.9; 8.4 percentage change in liver fat — p=0.585
N/A N=102 Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD
Primary: Number of Subjects With Incidence of Study Product Emergent Adverse Events (AEs) and Any Serious Adverse Events (SAEs) — 10; 8; 13; 2 participants
N/A N=57 Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic Fatty Liver Disease
Primary: Change in ALT Index — 42.238; 33.524; 36.667; 36.238 U/L
N/A N=14 Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD)
Liver Diseases
Primary: The Reproducibility of the Hepatic Triglyceride Content Measurement by MRS. — 13.0; 23.5; 4.4; 9.7 coefficient of variation
Phase 2 N=11 The University of Michigan Wellness for Liver Health Study
Nonalcoholic Fatty Liver Disease
Primary: Change in Liver Fat Content Using Liver MRI-derived Proton Density Fat Fraction — -7.06 percentage of liver lobe fat